Verge Genomics Stock

Drug Discovery

Sign up today and learn more about Verge Genomics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

Draper Associates


San Francisco CA, US

Total Funding


About Verge Genomics Stock

Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created a breakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease.


Funding History

June 2018$370K
June 2018$150K
June 2018$100K
June 2018$3.4M
June 2018$4.5M
June 2018$28.2M


Co-Founder & Chief Executive Officer

Alice Zhang

Chief Business Officer

Jane Rhodes


blog - Dec, 16 2017

Hard Tech Startups

strictlyvc - Feb, 24 2017

StrictlyVC: November 3, 2015

blog - Jan, 17 2017

Affordable Care

siliconbeat - Apr, 14 2016

End of the IPO? Tim Draper thinks so

blog - Nov, 8 2015

YC Digest - October 24-30

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: